Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABO2203
- Development stage
- Phase 1
- Lead developer
- Abogen Bioscience
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Parenteral, Injection
01
Overview
ABO2203 is an investigational mRNA-based bispecific T-cell engager (BiTE) therapy that encodes a bispecific antibody targeting both CD19 and CD3. The drug is designed to stimulate cytotoxic T lymphocytes by engaging the CD19 antigen on B cells and the CD3 complex on T cells, thereby redirecting T cells to eliminate pathogenic B cells. It is being developed primarily for refractory autoimmune diseases, including idiopathic inflammatory myopathies and lupus nephritis, particularly in patients who have not responded adequately to standard therapies. The product utilizes lipid nanoparticle delivery of mRNA encoding the bispecific antibody[1][2][3].
- Other names
- mRNA encoding CD19/CD3 T cell engager
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on ABO2203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABO2203.